All In Biotech

Drug Trial Radar · NCT00550238

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Jun 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

459

Actual

Start

Jul 2007

Primary completion

May 30, 2018

Study completion May 30, 2018

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 29, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.

Conditions

  • Parkinson's Disease Psychosis

Interventions

  • Pimavanserin tartrate (ACP-103)Drug

    Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)Time frame: From first to last study drug dose plus 30 days

Locations

135 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Gilbert, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Berkeley, California

  • Site not named

    Carson, California

  • Site not named

    Fountain Valley, California

  • Site not named

    Fresno, California

  • Site not named

    Irvine, California

  • Site not named

    La Habra, California

  • Site not named

    La Jolla, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Loma Linda, California

  • Site not named

    Oxnard, California

  • Site not named

    Pasadena, California

  • Site not named

    Reseda, California

  • Site not named

    Sunnyvale, California

  • Site not named

    Ventura, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Danbury, Connecticut

  • Site not named

    Fairfield, Connecticut

  • Site not named

    Farmington, Connecticut

  • Site not named

    Boca Raton, Florida

  • Site not named

    Bradenton, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Naples, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    Panama City, Florida

  • Site not named

    Pompano Beach, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Glenview, Illinois

  • Site not named

    Springfield, Illinois

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.